UAB and OrganoTherapeutics collaborate on PD therapeutics

Parkinson’s Disease affects millions of people worldwide, and there is an urgent need of novel therapeutics to stop the disease progression and increase patients’ life quality.

The Autonomous University of Barcelona (UAB) and OrganoTherapeutics now have agreed to jointly work on a program for the development of new therapeutics against Parkinson’s disease (PD). This is based on the work of Professor Salvador Ventura, who leads the Protein Folding and Conformational Disorders’ group at the Autonomous University of Barcelona. His team investigates protein structure, function and aggregation, with a focus on neurodegenerative diseases like Parkinson’s. In the future UAB and OT will jointly further develop candidate molecules which have been initially developed in the Ventura lab.